Compare S&P Global Inc (SPGI) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
S&P Global Inc vs TransMedics Group Inc — how do they compare? S&P Global Inc trades at $408.62 (market cap $120.48B), while TransMedics Group Inc trades at $87.57 (market cap $3.10B). The key difference: S&P Global Inc is far larger — about 38.9× TransMedics Group Inc's market cap, and S&P Global Inc pays a 0.95% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| SPGI | TMDX | |
|---|---|---|
Market Cap | $120.48B | $3.10B |
Sector | Financials | Technology |
52-Week High | $534.79 | $150.42 |
52-Week Low | $370.42 | $61.99 |
Enterprise Value | $131.97B | $3.49B |
Dividend Yield | 0.95% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
S&P Global (SPGI) trades at $409.55, down 0.34% with bearish technical signals despite strong fundamentals. The company reported Q2 2026 EPS of $4.83, beating estimates, with revenue growth accelerating to $15.34B in 2025. Analyst consensus remains strongly bullish with 85.7% buy ratings and a $523.20 price target, representing 28% upside potential from current levels.
SPGI presents a compelling investment case with robust profitability (30.5% net margin) and strategic AI partnerships, though technical indicators suggest near-term pressure. The key risk involves maintaining premium valuations (P/E 24.9) amid economic uncertainty, while institutional confidence remains high with aggressive buyback programs supporting shareholder returns.
TransMedics Group (TMDX) trades at $86.43, down 2.24% amid recent earnings misses but maintains strong analyst support with a $99.57 consensus target. The stock shows bullish technical signals with support at $84-87, though RSI levels suggest overbought conditions. Fundamentally, the company demonstrates robust profitability with 58.69% gross margins and 22.69% net income margins, despite recent quarterly earnings falling short of expectations.
Investment outlook remains positive given strong institutional backing and growth potential in organ transplant technology, though risks include ongoing fiduciary investigations and margin pressure from increased operating costs. The stock offers 15% upside to consensus targets but requires monitoring of Q3 earnings performance and legal developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About S&P Global Inc
S&P Global provides data and benchmarks to capital and commodity market participants. In 2021 and excluding IHS Markit, S&P Ratings was over 45% of the firm's revenue and over 55% of the firm's operating income. S&P Ratings is the largest credit rating agency in the world. The firm's other segments include Market Intelligence, Indices, and Platts. Market Intelligence provides desktop tools and other data solutions to investment banks, corporations, and other entities. Indices provides benchmarks for financial markets and is monetized through subscriptions, asset-based fees, and transaction-based royalties. Platts provides benchmarks to commodity markets, principally petroleum.
Read more on SPGI →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
